KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Non Operating Investment Income (2021 - 2022)

Xenon Pharmaceuticals (XENE) has disclosed Non Operating Investment Income for 2 consecutive years, with -$1.3 million as the latest value for Q2 2022.

  • Quarterly Non Operating Investment Income fell 7476.47% to -$1.3 million in Q2 2022 from the year-ago period, while the trailing twelve-month figure was -$4.7 million through Jun 2022, changed N/A year-over-year, with the annual reading at -$719000.0 for FY2021, 18075.0% down from the prior year.
  • Non Operating Investment Income for Q2 2022 was -$1.3 million at Xenon Pharmaceuticals, up from -$3.4 million in the prior quarter.
  • The five-year high for Non Operating Investment Income was -$17000.0 in Q2 2021, with the low at -$3.4 million in Q1 2022.